Parr McKnight Wealth Management Group’s Moderna MRNA Stock Holding History

Parr McKnight Wealth Management Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+3,201	New	+$166K	0.03%	217

Other funds holding MRNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Parr McKnight Wealth Management Group's MRNA Position: Q2 2026 in Review

Parr McKnight Wealth Management Group opened a new position in Moderna (MRNA) in Q2 2026: 3,201 shares worth $224K. The stake represents 0.03% of the portfolio and ranks #217 among its holdings.

399 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Parr McKnight Wealth Management Group held 3,201 shares of Moderna worth $224K as of Q2 2026.
Moderna was a new Parr McKnight Wealth Management Group position in Q2 2026.
Moderna made up 0.03% of Parr McKnight Wealth Management Group's portfolio in Q2 2026, its #217 holding.
399 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Parr McKnight Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.